MapLight’s $251m IPO sees schizophrenia drug developers on top
MapLight Therapeutics goals to boost round $251m through an preliminary public providing…
Neumora Therapeutics Initiates Phase 1 Study for Schizophrenia Drug NMRA-861
Neumora Therapeutics Inc. (NASDAQ:NMRA) is likely one of the best IPO stocks…
